. Company Overview We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohns disease (CD). Our Strategy We are committed to advancing a next generation of once daily, ...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-20 | 2025-12-31 | 0001357459-26-000004 | EDGAR | 76K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043859 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036402 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009226 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004093 | EDGAR | — |
| 2021-03-22 | 2020-12-31 | 0001171843-21-001965 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001171843-20-002061 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001171843-19-001917 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001171843-18-002404 | EDGAR | — |
| 2017-03-23 | 2016-12-31 | 0001171843-17-001704 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274262 | EDGAR | 39K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106587 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069204 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124664 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095432 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058644 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062215 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041459 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021374 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024748 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017248 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0000950170-22-009812 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001493152-26-014822 | EDGAR | 1K words |
| 2025-12-04 | 0001493152-25-026195 | EDGAR | — |
| 2025-10-22 | 0001493152-25-018922 | EDGAR | — |
| 2025-10-20 | 0001493152-25-018684 | EDGAR | — |
| 2025-10-16 | 0001493152-25-018324 | EDGAR | — |
| 2025-10-09 | 0001493152-25-017630 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015775 | EDGAR | — |
| 2025-09-18 | 0001493152-25-014071 | EDGAR | — |
| 2025-09-05 | 0001493152-25-012687 | EDGAR | — |
| 2025-07-25 | 0001641172-25-020896 | EDGAR | — |
446 total filings indexed. 414 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001357459 |
| Ticker | PALI |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.palisadebio.com |
| Listed | 2021-04-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report